Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Preoperative gadoxetic Acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection.

Matsuda M, Ichikawa T, Amemiya H, Maki A, Watanabe M, Kawaida H, Kono H, Sano K, Motosugi U, Fujii H.

HPB Surg. 2014;2014:641685. doi: 10.1155/2014/641685. Epub 2014 Feb 19.

2.

Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma.

Shim JH, Han S, Shin YM, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC.

J Magn Reson Imaging. 2015 Apr;41(4):1115-23. doi: 10.1002/jmri.24660. Epub 2014 May 20.

PMID:
24841479
4.

Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy.

Toyoda H, Kumada T, Tada T, Niinomi T, Ito T, Sone Y, Kaneoka Y, Maeda A.

J Hepatol. 2013 Jun;58(6):1174-80. doi: 10.1016/j.jhep.2013.01.030. Epub 2013 Jan 29.

PMID:
23376360
5.

Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.

Yoo SH, Choi JY, Jang JW, Bae SH, Yoon SK, Kim DG, Yoo YK, Rha SE, Lee YJ, Jung ES.

Ann Surg Oncol. 2013 Sep;20(9):2893-900. doi: 10.1245/s10434-013-3001-y. Epub 2013 May 7.

PMID:
23649931
6.

Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma.

Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon AH.

World J Surg. 2013 Apr;37(4):820-8. doi: 10.1007/s00268-013-1902-3.

PMID:
23340708
7.

Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus.

Ichikawa T, Sano K, Morisaka H.

Liver Cancer. 2014 May;3(2):97-107. doi: 10.1159/000343865. Review.

8.

Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?

Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H.

Ann Surg. 2003 Oct;238(4):508-18; discussion 518-9.

9.

Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease?

Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhu J, Zhang W, Hu J.

Dig Dis Sci. 2013 Nov;58(11):3313-25. doi: 10.1007/s10620-013-2790-y. Epub 2013 Jul 25.

PMID:
23884757
10.

Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria.

Rhee H, Kim MJ, Park YN, Choi JS, Kim KS.

J Magn Reson Imaging. 2012 Feb;35(2):393-8. doi: 10.1002/jmri.22828. Epub 2011 Oct 11.

PMID:
21990116
11.
12.

Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S.

Surgery. 2007 Mar;141(3):330-9. Epub 2006 Nov 1.

PMID:
17349844
13.

Longterm prognosis after hepatic resection for small hepatocellular carcinoma.

Shimozawa N, Hanazaki K.

J Am Coll Surg. 2004 Mar;198(3):356-65.

PMID:
14992736
14.
15.

Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.

Granito A, Galassi M, Piscaglia F, Romanini L, Lucidi V, Renzulli M, Borghi A, Grazioli L, Golfieri R, Bolondi L.

Aliment Pharmacol Ther. 2013 Feb;37(3):355-63. doi: 10.1111/apt.12166. Epub 2012 Dec 2.

16.

Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, Lee WJ, Lim HK.

AJR Am J Roentgenol. 2009 Jun;192(6):1675-81. doi: 10.2214/AJR.08.1262.

PMID:
19457834
17.

Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases.

Chung WS, Kim MJ, Chung YE, Kim YE, Park MS, Choi JY, Kim KW.

J Magn Reson Imaging. 2011 Aug;34(2):345-53. doi: 10.1002/jmri.22671. Epub 2011 Jun 23.

PMID:
21702068
18.

Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma.

Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A.

Eur J Radiol. 2012 Nov;81(11):3002-9. doi: 10.1016/j.ejrad.2012.03.029. Epub 2012 Jun 29.

PMID:
22748558
19.

Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases?

Tajima T, Akahane M, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, Kokudo N, Ohtomo K.

Jpn J Radiol. 2012 Oct;30(8):648-58. doi: 10.1007/s11604-012-0105-4. Epub 2012 Jul 18.

PMID:
22836904
20.

Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China.

Huang ZY, Liang BY, Xiong M, Zhan DQ, Wei S, Wang GP, Chen YF, Chen XP.

Ann Surg Oncol. 2012 Aug;19(8):2515-25. doi: 10.1245/s10434-012-2269-7. Epub 2012 Mar 7.

PMID:
22395985
Items per page

Supplemental Content

Write to the Help Desk